Aspirin therapy is supported for both secondary and primary prevention of cardiovascular events in selected at-risk adult populations, though current practice patterns may be suboptimal.
Does aspirin prevent cardiovascular events in at-risk adult patients for primary and secondary prevention?
Aspirin remains a simple and inexpensive prophylactic measure for primary and secondary prevention of cardiovascular disease in at-risk adults, though its clinical use may be suboptimal.
Aspirin therapy is well-accepted as an agent for the secondary prevention of cardiovascular events and current guidelines also define a role for aspirin in primary prevention. In this review, we describe the seminal trials of aspirin use in the context of current guidelines, discuss factors that may influence the effectiveness of aspirin therapy for cardiovascular disease prevention, and briefly examine patterns of use. The body of evidence supports a role for aspirin in both secondary and primary prevention of cardiovascular events in selected population groups, but practice patterns may be suboptimal. As a simple and inexpensive prophylactic measure for cardiovascular disease, aspirin use should be carefully considered in all at-risk adult patients, and further measures, including patient education, are necessary to ensure its proper use.
Ittaman et al. (Wed,) conducted a review in Cardiovascular disease. Aspirin was evaluated on Cardiovascular events. Aspirin therapy is supported for both secondary and primary prevention of cardiovascular events in selected at-risk adult populations, though current practice patterns may be suboptimal.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: